Shofu Inc.

7979.T
Medical Instruments & Supplies
2026/11/05 12:54 Updated
Market Cap: $503.9M (¥79.9B)
Stock Price: $14.16 (¥2,244)
Exchange Rate: 1 USD = ¥158.48

Financial Summary for the Second Quarter of the Fiscal Year Ending March 2027 (Interim) [Japanese GAAP] (Consolidated)

Net sales were 21,406 million yen, up 12.1% year-over-year; operating income was 3,432 million yen (+22.0%); ordinary income was 3,486 million yen (+17.7%); and interim net income attributable to owners of parent was 3,944 million yen (+51.9%), marking the highest interim results on record. By segment, Dental performed strongly, Nail decelerated, and Other recorded slight increases. Full-year forecasts remain unchanged. Total assets at the end of the interim period were 62,546 million yen, with a shareholders' equity ratio of 82.9%. A dividend of 39 yen is planned at the end of Q2, with a full-year total expected of 67 yen. The company completed the absorption-type merger with Shofu Biofix, as part of corporate integration.

Importance:
Page Updated: November 5, 2026
IR Disclosure Date: November 5, 2026

Key Figures

  • Net Sales: 21,406 million yen (YoY +12.1%)
  • Operating Income: 3,432 million yen (YoY +22.0%)
  • Interim Net Income Attributable to Owners of Parent: 3,944 million yen (YoY +51.9%)

AI要約

Overview of Results

For the interim period, net sales amounted to 21,406 million yen (YoY +12.1%), driven by steady performance across multiple domestic and international segments. Dental-related products contributed solidly, overseas sales increased, and foreign exchange effects were positive. Operating income was 3,432 million yen (+22.0%), ordinary income was 3,486 million yen (+17.7%), and interim net income was 3,944 million yen (+51.9%), marking record-high interim levels. The financial position remained strong with total assets of 62,546 million yen and a shareholders' equity ratio of 82.9%.

Outlook and Capital Policy

Full-year earnings forecasts remain unchanged from those announced. Regarding dividends, 39 yen is planned at the end of the second quarter, with a full-year plan of 67 yen. During the interim period, the company completed an absorption-type merger with Shofu Biofix Inc., strengthening its digital dentistry capabilities. Going forward, the company will focus on further expanding the Dental business and stabilizing profitability in the Nail and Other businesses.

Revenue Trend

Operating Income Trend

Revenue by Segment

This page uses AI to summarize IR materials from TDnet. Please refer to the original document for investment decisions.

Shofu Inc.

Company overview · Stock price · Financial data · All IR

View company page →